Tafasitamab

Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19[1][2].

Product Specifications

CAS Number

[1422527-84-1]

Product Name Alternative

XmAb5574; MOR00208; Tafasitamab-cxix; MOR-208

UNSPSC

12352203

Target

Apoptosis

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tafasitamab.html

Purity

99.71

Solubility

H2O

Smiles

[Tafasitamab]

Molecular Weight

(147.42 kDa)

References & Citations

[1]Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29.|[2]Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res